Gerard I. Evan

Gerard I. Evan

Auto-generated profile, based on publicly available information

Gerard I. Evan

The Francis Crick Institute, London, UK

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2000 in Nature
Verified
Journal Article
Closed access
PMPascal Meier
Pascal Meier
AFAndrew Finch
Andrew Finch
GEGerard Evan
Gerard Evan

17 August 2008 in Nature
Verified
Journal Article
Closed access
PDF file
LSLaura Soucek
Laura Soucek
JWJonathan Whitfield
Jonathan Whitfield
CMCarla P. Martins
Carla P. Martins
AFAndrew J. Finch
Andrew J. Finch
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
GEGerard I. Evan
Gerard I. Evan

1 November 2017 in Cell
Verified
Journal Article
Open access
RKRoderik M. Kortlever
Roderik M. Kortlever
NSNicole M. Sodir
Nicole M. Sodir
CWCatherine H. Wilson
Catherine H. Wilson
DBDeborah L. Burkhart
Deborah L. Burkhart
LPLuca Pellegrinet
Luca Pellegrinet
GEGerard I. Evan
Gerard I. Evan
The two oncogenes KRas and Myc cooperate to drive tumorigenesis, but the mechanism underlying this remains unclear. In a mouse lung model of KRasG12D-driven adenomas, we find that co-activation of Myc drives the immediate transition to highly proliferative and invasive adenocarcinomas marked by highly inflammatory, angiogenic, and immune-suppressed stroma. We identify epithelial-derived signaling molecules CCL9 and IL-23 as the principal instructing signals for stromal reprogramming. CCL9 mediates recruitment of macrophages, angiogenesis, and PD-L1-dependent expulsion of T and B cells. IL-23 orchestrates exclusion of adaptive T and B cells and innate immune NK cells. Co-blockade of both CCL9 and IL-23 abrogates Myc-induced tumor progression. Subsequent deactivation of Myc in established adenocarcinomas triggers immediate reversal of all stromal changes and tumor regression, which are independent of CD4+CD8+ T cells but substantially dependent on returning NK cells. We show that Myc extensively programs an immune suppressive stroma that is obligatory for tumor progression.

13 April 2023 in Nature
Verified
Journal Article
Open access
PDF file
CAChristopher Abbosh
Christopher Abbosh
AFAlexander M. Frankell
Alexander M. Frankell
THThomas Harrison
Thomas Harrison
JKJudit Kisistok
Judit Kisistok
AGAaron Garnett
Aaron Garnett
CSCharles Swanton
Charles Swanton
Circulating tumour DNA (ctDNA) can be used to detect and profile residual tumour cells persisting after curative intent therapy1. The study of large patient cohorts incorporating longitudinal plasma sampling and extended follow-up is required to determine the role of ctDNA as a phylogenetic biomarker of relapse in early-stage non-small-cell lung cancer (NSCLC). Here we developed ctDNA methods tracking a median of 200 mutations identified in resected NSCLC tissue across 1,069 plasma samples collected from 197 patients enrolled in the TRACERx study2. A lack of preoperative ctDNA detection distinguished biologically indolent lung adenocarcinoma with good clinical outcome. Postoperative plasma analyses were interpreted within the context of standard-of-care radiological surveillance and administration of cytotoxic adjuvant therapy. Landmark analyses of plasma samples collected within 120 days after surgery revealed ctDNA detection in 25% of patients, including 49% of all patients who experienced clinical relapse; 3 to 6 monthly ctDNA surveillance identified impending disease relapse in an additional 20% of landmark-negative patients. We developed a bioinformatic tool (ECLIPSE) for non-invasive tracking of subclonal architecture at low ctDNA levels. ECLIPSE identified patients with polyclonal metastatic dissemination, which was associated with a poor clinical outcome. By measuring subclone cancer cell fractions in preoperative plasma, we found that subclones seeding future metastases were significantly more expanded compared with non-metastatic subclones. Our findings will support (neo)adjuvant trial advances and provide insights into the process of metastatic dissemination using low-ctDNA-level liquid biopsy.

1 December 2008 in Cancer Cell
Verified
Journal Article
Closed access
Daniel J. MurphyDaniel J. Murphy
Daniel J. Murphy
MJMelissa R. Junttila
Melissa R. Junttila
LPLaurent Pouyet
Laurent Pouyet
AKAnthony Karnezis
Anthony Karnezis
KSKsenya Shchors
Ksenya Shchors
GEGerard I. Evan
Gerard I. Evan

1 March 2013 in Genes & Development
Verified
Journal Article
Open access
PDF file
LSLaura Soucek
Laura Soucek
JWJonathan R. Whitfield
Jonathan R. Whitfield
NSNicole M. Sodir
Nicole M. Sodir
DMDaniel Massó-Vallés
Daniel Massó-Vallés
ESErika Serrano
Erika Serrano
GEGerard I. Evan
Gerard I. Evan
The principal reason for failure of targeted cancer therapies is the emergence of resistant clones that regenerate the tumor. Therapeutic efficacy therefore depends on not only how effectively a drug inhibits its target, but also the innate or adaptive functional redundancy of that target and its attendant pathway. In this regard, the Myc transcription factors are intriguing therapeutic targets because they serve the unique and irreplaceable role of coordinating expression of the many diverse genes that, together, are required for somatic cell proliferation. Furthermore, Myc expression is deregulated in most—perhaps all—cancers, underscoring its irreplaceable role in proliferation. We previously showed in a preclinical mouse model of non-small-cell lung cancer that systemic Myc inhibition using the dominant-negative Myc mutant Omomyc exerts a dramatic therapeutic impact, triggering rapid regression of tumors with only mild and fully reversible side effects. Using protracted episodic expression of Omomyc, we now demonstrate that metronomic Myc inhibition not only contains Ras-driven lung tumors indefinitely, but also leads to their progressive eradication. Hence, Myc does indeed serve a unique and nondegenerate role in lung tumor maintenance that cannot be complemented by any adaptive mechanism, even in the most aggressive p53-deficient tumors. These data endorse Myc as a compelling cancer drug target.